STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1174 by analyst upside · 2026-06-27
ZYME
Zymeworks Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+62.4%
implied upside to consensus target
Current Price $24.15
Consensus Target $39.23
Bull Target $58.0
Bear Target $28.0
Analysts Covering 13
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
11
Hold
0
Sell
0
52-Week Low $11.51
52-Week High $29.75
YTD Return -9.3%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E 35.3x
EPS (TTM) $-1.37
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $81M
Profit Margin -126.3%
52-WEEK RANGE
52-Week Low $11.51
52-Week High $29.75
Current Price $24.15
Bear Target $28.0
Bull Target $58.0
● Now $24.15 ● Target $39.23
TRADING DATA
Avg Volume 652K
YTD Return -9.3%
Analyst Count 13
Consensus Buy
Upside to Target +62.4%
Last Updated 2026-06-27

ANALYST SUMMARY

Zymeworks Inc. (ZYME) is currently trading at $24.15 with a Wall Street consensus price target of $39.23, implying potential upside of 62.4% over the next 12 months. 13 analysts currently cover ZYME, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $58.0, while the most cautious has a target of $28.0.

ZYME operates in the Healthcare sector with a market capitalisation of $2B. The stock is down 9.3% year-to-date and is currently trading near the upper end of its 52-week range of $11.51 – $29.75.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ZYME, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-06-03 31% win rate (48 calls)
Wells Fargo — Reiterated
Overweight → Overweight 2026-05-08 Building track record
Evercore ISI Group — Reiterated
Outperform → Outperform 2026-03-09 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-03-06 31% win rate (48 calls)
Stifel — Reiterated
Buy → Buy 2026-03-03 Building track record
Leerink Partners — Reiterated
Outperform → Outperform 2026-03-03 29% win rate (7 calls)
Truist Securities ● Initiated
Buy 2025-12-17 Building track record
Wells Fargo ↑ Upgrade
Equal-Weight → Overweight 2025-12-12 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
52
out of 100
Coverage depth
20/30
Consensus clarity
5/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →